Abbott Laboratories (ABT)

They have combined for 118 years of consecutive dividend increases.

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

These stocks check off multiple boxes for income investors.

A rare yield, Dividend King status, and a steady healthcare business may be creating one of its most interesting income setups in years.

This company, which has raised its dividend for 54 consecutive years, is on sale.

How does a nearly 3% (and growing) dividend yield sound?

Abbott Labs is a balance of income and growth.

They offer investors very different value propositions.

Various concerns weighed on appetite for stocks in recent weeks.

These stocks pay juicy dividends but also offer much more.

Abbott Laboratories (NYSE:ABT) reported upbeat Q1 earnings but lowered its 2026 outlook, including dilution from Exact Sciences acquisition.

It essentially met analyst expectations for its inaugural quarter of 2026.

Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.

Abbott (ABT) Q1 2026 Earnings Call Transcript

Healthcare product and device company Abbott Laboratories (NYSE:ABT) announced better-than-expected revenue in Q1 CY2026, with sales up 7.8% year on year to ...

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66

Abbott Laboratories (NYSE: ABT) to report Q1 earnings on April 16, expected EPS of $1.15 and revenue of $11B. Acquired Exact Sciences, stock up 0.4%.